Preclinical research raised concern regarding the foetal effects of using sugammadex during pregnancy. However, to the best of our knowledge, the placental transfer of sugammadex has never been measured. As these data would be critical in assessing the foetal effects after maternal administration of sugammadex, it is warranted to measure the placental transfer of sugammadex. The aim of this project is to measure the placental transfer of sugammadex in the human placenta by using the ex vivo human placenta perfusion model.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
16
In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Foetal-maternal ratio of the drug
Drug concentrations of samples from the maternal and fetal compartment in the ex-vivo placenta perfusion model will be determined by high performance liquid chromatography and mass spectrometry.
Time frame: On the same day as collection of placenta
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.